Page 27 - ARNM-1-2

Advances in Radiotherapy
& Nuclear Medicine FAP-targeted RLT in cancer

Table 3. Summary of the studies involving human fibroblast activation protein inhibitor (FAPI)‑based radionuclide therapy
Study (Country) Tracers Injected activity No. of Type of cancer Response Adverse events
patients (no. of patients) (RECIST)
Lindner et al. [11] 90 Y-FAPI-04 2.9 GBq, 1 cycle 2 Breast cancer (2) NA None
(Germany)
Lindner et al. [12] 90 Y-FAPI-46 6 GBq, 2 cycles 2 Pancreatic cancer (1), NA NA
(Germany) ovarian cancer (1)
Jokar et al. [43] (Iran) 177 Lu-FAPI-46 3.7 GBq, 2 cycles 1 Breast cancer (1) NA NA
Rathke et al. [32] 90 Y-FAPI-46 7.4 GBq (Cumulative 1 Breast cancer (1) PD NA
(Germany) 28.1 GBq), 4 cycles
Assadi et al. [44] (Iran) 177 Lu-FAPI-46 3.7 GBq (1.85–13.7 18 Ovarian cancer (2), 12 SD, 6 PD Anemia G3 (1);
GBq), 36 cycles sarcomas (1), colon leukopenia G1 (1);
cancer (3), breast thrombocytopenia
cancer (5), pancreatic G1 (1)
cancer (2), prostate
cancer (2), cervical
cancer (1), lung
cancer (1), thyroid
cancer (1)
Ballal et al. [45] (India) 177 Lu-DOTA.SA.FAPI; 2.96 GBq SA.FAPI and 10 Thyroid cancer (5), SA.FAPIPD Anemia G3 (1);
177 Lu-DOTAGA. 1.48 GBq (SA.FAPI) , breast cancer (4), (SA.FAPi) thrombocytopenia
2
2
(SA.FAPI) 17 cycles paraganglioma (1) clinical G1 (1)
2
response
Ballal et al. [13] (India) 177 Lu-DOTA.SA.FAPi 3.2 GBq, 1 cycle 1 Breast cancer (1) NA NA
Ballal et al. [51] (India) 177 Lu-DOTAGA.(SA. 8.2±2.7 GBq, 45 cycles 15 Thyroid cancer (15) 4 PR, 3 SD, Diarrhea G1 (1)
FAPI) others NA
2
Kuyumcu et al. [46] 177 Lu-FAPI-04 267.5±8.6 GBq, 4 cycles 4 Breast cancer (1), NA NA
(Turkey) thymic carcinoma (1),
thyroid cancer (1),
ovarian cancer (1)
Kratochwil et al. [33] 153 Sm-FAPI-46, 20 GBq Sm-FAPI-46, 1 Soft tissue sarcoma SD NA
153
(Germany) 90 Y-FAPI-46 and 8 GBq Y-FAPI-46 (1)
90
Fu et al. [34] 177 Lu-FAPI-46 3.7 GBq, 1 cycle 1 Nasopharyngeal PD, mixed None
(China) carcinoma (1) response
Baum et al. [47] 177 Lu-FAP-2286 5.8±2.0 GBq, 22 cycle 11 Pancreatic cancer 9 PD, 2 SD Headache G1 (4), G2 (4);
(Germany) (5), breast cancer (4), Anemia G1 (1), G2 (2);
rectum tumor (1), leukopenia G2 (2), G3 (1);
ovary cancer (1) pancytopenia (1); pain
flare-up G3 (1)
Ferdinandus et al. [48] 90 Y-FAPI-46 3.8 GBq in the 1 cycle 9 Pancreatic cancer 4 PD, 4 SD, Anemia G1 (2), G2 (2)
st
(Germany) and 7.4 GBq in the 2 (3), Sarcomas (4), 1 NA and G3 (4); renal G (1),
nd
cycle chordoma (1), G2 (1) and liver G1 (1),
neuroendocrine G2 (12), G3 (1), G4 (1);
tumor (1) pancreatobiliary G1 (1),
G3 (1), G4 (1)
Fendler et al. 90 Y-FAPI-46 3.7–7.4 GBq, 47 cycles 21 Sarcoma (16), 1 PR, 8 PD, Anemia G3 (6);
[49]
(Germany) pancreatic cancer (3), 7 SD, and thrombocytopenia
prostate cancer (1), others NA G3 (6)
gastric cancer (1)
Fu et al. [72] (China) 177 Lu-FAPI-46 5.55 GBq (cumulative 1 Thyroid cancer (1) SD Pain flare-up
16.7 GBq), 4 cycles
Kaghazchi et al. (Iran) 177 Lu-FAPI-46 1.85 GBq, 1 cycle 1 Pancreatic cancer (1) PR Pain flare-up
[50]
Rao et al. (China) 177 Lu-FAP-2286 7.0 GBq, 1 cycle 1 Lung squamous cell PR None
[73]
carcinoma (1)
Abbreviations: NA: Not available; PD: Progressive disease; PR: Partial response; RECIST: Response Evaluation Criteria in Solid Tumors; SD: Stable disease.

Volume 1 Issue 2 (2023) 6 https://doi.org/10.36922/arnm.1667